Gene-hacking unicorn Ginkgo Bioworks pushed further into medicine with the acquisition of Warp Drive Bio’s genome mining platform and its antibiotics discovery deal with Roche. “This is a big part of the future of Ginkgo,” CEO Jason Kelly told Forbes.